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Gamma glutamyltransferase and 
risk of dementia in prediabetes and 
diabetes
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Byung-Wan Lee  2,3,8, Eun Seok Kang  2,3,8, Bong-Soo cha2,3,8, Zobair M Younossi7 &  
Yong-ho Lee  2,3,8,9 ✉
Diabetes is associated with cognitive impairment and greater risk for dementia, but the role of gamma-
glutamyltransferase (γ-GT) in dementia has not been elucidated. We determined incident dementia 
including Alzheimer’s disease and vascular dementia, analyzing data from participants aged 40 years 
or older in the National Health Insurance Database, collected by the National Health Insurance Service 
in Korea, from January 2009 to December 2015. During a median follow-up of 7.6 years, 272,657 
participants were diagnosed as having dementia. Higher serum γ-GT was associated with increased 
risk of dementia (HR = 1.22, 95% CI = 1.20–1.24), and had a strong positive association with early onset 
dementia (HR = 1.32, 95% CI = 1.24–1.40). An additive impact of higher γ-GT on dementia was observed 
regardless of glycemic status, and prevalent diabetes with the highest γ-GT quartile had a 1.8-fold 
increased dementia risk (HR = 1.82, 95% CI = 1.78–1.85). This effect of γ-GT concentration in diabetes 
was more prominent in individuals with vascular dementia (HR = 1.94, 95% CI = 1.84–2.04). In subgroup 
analysis, young age, male sex, and relatively healthy subjects with a higher γ-GT quartile had more 
increased dementia risk. In conclusion, γ-GT concentration as well as glycemic status could be a future 
risk factor for dementia in the general population.
Over the past few decades, population aging has produced increased cases of dementia. Dementia is the leading 
cause of chronic disability in elderly individuals1,2. The worldwide prevalence of dementia was approximately 
35.6 million in 2010, and the number of individuals living with dementia is expected to double every 20 years3. In 
addition, early onset dementia (EOD) can lead to significant socioeconomic burden and impaired quality of life 
in the younger population4,5, Along with genetic risk factors, inflammatory pathways and vascular factors have 
been implicated in the development of dementia. It is reported that chronic systemic inflammation could lead to 
cognitive dysfunction and substantially increase the risk of cognitive impairment6. Among chronic inflamma-
tory diseases, diabetes is thought to play an important role in cognitive dysfunction7. Atherosclerosis is not only 
implicated in vascular dementia (VaD), but is also an independent risk factor for Alzheimer’s disease (AD), which 
suggests its importance in dementia regardless of subtype8.
Gamma-glutamyltransferase (γ-GT) is known as a marker of hepatobiliary disease9. γ-GT is a highly sensitive 
enzyme whose level may be elevated in liver disease such as non-alcoholic fatty liver disease (NAFLD). Recent 
studies demonstrate the possible role of γ-GT in systemic diseases; large population-based studies show the asso-
ciation between γ-GT and vascular disease10,11. Furthermore, correlations between γ-GT in inflammation12, and 
oxidation13 have been demonstrated. In this context, it is plausible that elevated γ-GT in liver disease shares some 
common mechanisms in dementia. We hypothesized that γ-GT may be independently associated with dementia. 
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Therefore, the aim of this study was to investigate the impact of γ-GT in dementia and the association between 
γ-GT, diabetes, and dementia risk in a general population.
Results
Study population. Among a study population of 6,595,271 adults, 272,657 had a new diagnosis of demen-
tia during the follow-up period (Fig. 1). The mean duration of follow-up was 7.6 years, and the overall inci-
dence of dementia during the entire study period was 4.1% (272,657/6,595,271), and AD in late oneset dementia 
(LOD) ranked the highest incidence (11.4%). The mean age of the study population was 55.9 years, and the mean 
age of dementia diagnosis was 76.5 years (Table 1). Individuals with AD were older than those with VaD, and 
participants with incident dementia had higher blood pressure, fasting plasma glucose, and total cholesterol at 
baseline compared to participants who remained dementia-free over follow-up (all P < 0.001). The proportion 
of hypertension, dyslipidemia, myocardial infarction, ischemic stroke, prevalent diabetes, and incident diabetes 
was higher among participants who developed dementia over follow-up. Regarding γ-GT quartiles, body mass 
index (BMI), blood pressure, total cholesterol, aspartate transaminase (AST), and alanine transferase (ALT) were 
increased from lowest quartile to highest quartile (Table 2). Glycemic status and fasting plasma glucose value was 
higher for greater quartile of γ-GT.
incidence and risk for dementia according to serum γ-GT levels. To explore the relationship 
between baseline γ-GT and dementia risk, we categorized by sex-specific γ-GT decile and analyzed hazard ratios 
(HRs) for each group. Dementia risk increased gradually from the lowest to highest γ-GT decile (HR = 1.22, 
95% confidence interval [CI] = 1.20–1.24 for the highest γ-GT quartile; Fig. 2). Among γ-GT quartiles, dementia 
incidence tended to increase from lowest to highest γ-GT quartiles (3.9 vs. 4.0 vs. 4.3 vs. 4.4, P < 0.001; Table 2). 
This result was observed regardless of age group; however, a much stronger association between dementia risk 
and γ-GT concentration was shown in EOD (HR = 1.32, 95% CI = 1.24–1.40) compared to LOD (HR = 1.18, 
95% CI = 1.16–1.20). Regarding dementia subtype, the increasing risk pattern according to γ-GT concentra-
tion for AD (HR = 1.21, 95% CI = 1.18–1.23) was comparable to VaD (HR = 1.26, 95% CI = 1.20–1.32). The 
dementia-free survival curve also demonstrated that higher γ-GT quartile was associated with incident dementia 
regardless of subtype (Fig. 3). In the Cox analysis model, the highest γ-GT quartile was associated with higher 
overall dementia incidence by 16% compared to the lowest γ-GT group (HR = 1.16; 95% CI = 1.15–1.17, Table 3). 
Although incidence of LOD was higher than that of EOD, the risk for individuals with higher γ-GT values was 
more pronounced for EOD (HR = 1.22, 95% CI = 1.17–1.27) compared to LOD (HR = 1.13, 95% CI = 1.12–1.14). 
Similar patterns were observed for incidence of AD (HR = 1.14, 95% CI = 1.13–1.16) and VaD (HR = 1.22, 95% 
CI = 1.18–1.26). Individuals with NAFLD had increased risk for overall dementia types, particularly vascular 
dementia (HR = 1.11, 95% CI = 1.08–1.15).
Risk for dementia by glycemic status. The incidence of dementia was higher as glycemic status was 
increased (Table 4). Individuals with prevalent diabetes had a 1.6-fold greater risk for dementia compared to those 
Figure 1. Study flow. NHIS, Korean National Health Insurance Service.
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with normal glucose concentration (HR = 1.60, 95% CI = 1.58–1.62) and this phenomenon was more prominent 
in EOD (HR = 1.73, 95% CI = 1.66–1.81) compared to LOD (HR = 1.55, 95% CI = 1.53–1.57). The risk for VaD 
(HR = 1.67, 95% CI = 1.62–1.72) was slightly higher compared to that of AD (HR = 1.55, 95% CI = 1.55–1.59). 
The difference in dementia risk according to glycemic status was also observed in the Kaplan-Meier curve and a 
similar pattern was shown in both AD and VaD (Fig. 4). As shown in Table 5, the risk for dementia ranked the 
highest in the treatment failure group. Subjects who fail to treat diabetes had a 2.07-fold greater risk for EOD.
Combined effects of γ-GT levels and glycemic status on dementia risk. Compared to non-diabetic 
individuals with the lowest γ-GT concentration, those with prevalent diabetes and highest γ-GT concentrations 
had an approximately 1.8-fold increased risk of dementia (HR = 1.82, 95% CI = 1.78–1.85; Fig. 5A). This additive 
effect of γ-GT concentration in diabetes was more prominent in VaD (HR = 1.94, 95% CI = 1.84–2.04; Fig. 5B) 
than AD (HR = 1.76, 95% CI = 1.72–1.80; Fig. 5C). When analyzing the risk of dementia according to γ-GT quar-
tiles among individuals with the same glycemic status (lowest γ-GT quartile as reference in each glycemic status 
group), the elevated hazard ratio for overall dementia was the most prominent for normoglycemia (HR = 1.18, 
95% CI = 1.16–1.20; Fig. 5D) and prevalent diabetes and this pattern was similar in both EOD and LOD. The 
highest γ-GT quartile had was associated higher dementia risk regardless of glycemic status. In prevalent diabetes 
and incident diabetes in the younger age group, dementia risk was slightly lower in the second and third γ-GT 
quartiles and then increased in the highest quartile, representing a J shape (Fig. 5E). The risk for LOD in nor-
moglycemic individuals in the highest γ-GT quartile was lower than EOD risk (HR = 1.14, 95% CI = 1.13–1.16; 
Fig. 5F).
Association between γ-GT levels and the risk of dementia by other comorbid conditions. The 
association between γ-GT level and risk of dementia was still significant regardless of other clinical conditions 
(Fig. 6). The risk for highest γ-GT quartile in EOD was higher than in LOD for both sexes, and male individuals 
under 60 years old were had the greatest dementia risk, particularly for VaD (HR = 1.40, 95% CI = 1.21–1.61). 
VaD risk with higher γ-GT values was greater than AD risk regardless of hypertension, cardiovascular disease, 
and obesity. Regardless of dementia subtype, the impact of γ-GT on incident dementia was stronger in individuals 






(N = 272,657) P value
Age (years) at survey, mean (SD) 55.9 (10.4) 55.2 (10.0) 71.7 (7.9) <0.001
Age ≥60 years, N (%) 2,244,030 (34.0) 1,991,288 (31.5) 252,742 (92.7) <0.001
Male, N (%) 2,467,983 (37.4) 2,386,726 (37.8) 81,257 (29.8) <0.001
BMI (kg/m2), mean (SD) 23.9 (3.0) 23.9 (3.0) 23.7 (3.3) <0.001
Obesity, N (%)* 2,199,321 (33.3) 211,0251 (33.4) 89,070 (32.7) <0.001
SBP (mmHg), mean (SD) 124.5 (16.2) 124.2 (16.1) 131.2 (17.5) <0.001
DBP (mmHg), mean (SD) 77.0 (10.3) 77.0 (10.3) 78.9 (10.5) <0.001
FPG (mg/dL), mean (SD) 98.1 (24.6) 97.8 (24.2) 105.0 (32.5) <0.001
Total cholesterol (mg/dL), mean (SD) 198.2 (37.0) 198.2 (36.9) 200.0 (39.7) <0.001
γ-GT (IU/L), median (IQR) 24.0 (24.0–24.0) 24.1 (24.0–24.1) 23.8 (23.7–23.8) <0.001
AST (IU/L), median (IQR) 24.4 (24.4–24.4) 24.4 (24.4–24.4) 25.2 (25.2–25.2) <0.001
ALT (IU/L), median (IQR) 21.9 (21.9–21.9) 22.0 (22.0–22.0) 20.3 (20.3–20.4) <0.001
Glycemic status <0.001
Normoglycemia, N (%) 198,210 (3.0) 186,322 (3.0) 11,888 (4.4)
IFG, N (%) 4,372,692 (66.3) 4,229,999 (66.9) 142,693 (52.3)
Incident diabetes, N (%) 1,495,510 (23.7) 1,428,522 (22.6) 66,988 (24.6)
Prevalent diabetes, N (%) 528,859 (8.0) 477,771 (7.6) 51,088 (18.7)
Hypertension, N (%) 2,285,042 (34.6) 2,118,179 (33.5) 166,863 (61.2) <0.001
Dyslipidemia, N (%) 1,394,308 (21.1) 1,313,660 (20.8) 80,648 (29.6) <0.001
Myocardial infarction, N (%) 41,228 (0.6) 37,295 (0.6) 3,933 (1.4) <0.001
Stroke, N (%) 178,144 (2.7) 146,557 (2.3) 31,587 (11.6) <0.001
Current smoker, N (%) 722,293 (11.0) 700,470 (11.1) 21,823 (8.0) <0.001
Heavy drinker, N (%) 1,204,882 (18.3) 1,185,234 (18.8) 19,648 (7.2) <0.001
Regular exercise, N (%) 3,065,437 (46.5) 2,976,362 (47.1) 89,075 (32.7) <0.001
Income, lowest quartile, N (%) 1,399,220 (21.2) 1,343,661 (21.3) 55,559 (20.4) <0.001
Table 1. Baseline characteristics of study population. Data for continuous variables were expressed as either 
mean ± standard deviation, or mean (interquartile range) and categorical variables were expressed as number 
(percent). *Obesity was defined as body mass index >25 kg/m2 per Asian-Pacific definition. Abbreviations: 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 
γ-GT, gamma-glutamyltransferase; AST, aspartate transaminase; ALT, alanine transferase; IFG, impaired fasting 
glucose.
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an increased dementia risk compared to individuals without heavy alcohol use, and VaD risk was the highest in 
heavy alcohol use group (HR = 1.44, 95% CI = 1.30–1.61).
Discussion
In this large, national population-based study, we demonstrated that serum γ-GT levels had a linear relationship 
with risk of developing dementia, independent of glycemic status and other important potential confounders. 
In particular, the influences of higher γ-GT levels and diabetes on developing dementia were much stronger for 
EOD than for LOD. γ-GT concentrations and glycemic status had an additive impact on dementia incidence. 
Regarding glycemic categories, the association between higher serum γ-GT concentration and dementia risk was 
more profound in the normoglycemic group compared with impaired fasting glucose (IFG) or diabetes. In addi-
tion, the increased risk of developing VaD according to γ-GT concentration was greater compared to AD risk.
The impact of diabetes on dementia has been established, since other studies demonstrated chronic exposure 
to hyperglycemia may increase cognitive dysfunction14,15. Although there has been no study on the diabetes 
increases the risk of EOD, the evidence that average for dementia translation was earlier in patients with type 2 
diabetes compared to the patients without diabetes16 accords our result. The remarkably increased EOD risk for 
treatment failure group might reflect that failure to treat diabetes may accelerate progression to cognitive decline 
and the importance of glucose control in young adults. Even among individuals without diabetes, the risk for 
future dementia gradually increased with elevated glucose level, and a lower glucose concentration was inversely 
associated with dementia risk14. In addition, even among individuals without diabetes, dementia risk increased as 
the glycemic status worsened, to IFG or incident diabetes. Notably, the association of γ-GT levels and dementia 
outcome was linear in the normoglycemic group in the current study. As to glycemic status, higher γ-GT con-
centrations in individuals with normal glucose levels had the highest dementia risk. As diabetes and dementia 
share common features15, and diabetes is often co-morbid with dementia17, the influence of elevated GGT in the 
normoglycemic group may be more pronounced.






γ-GT Q4 (highest) 
(N = 1,599,790) P value
γ-GT (IU/L), median (IQR) 12.0 (10.0–14.0) 17.0 (15.0–23.0) 23.0 (20.0–32.0) 46.0 (32.0–67.0) <0.001
γ-GT (IU/L), cutoff in men ≤19.0 20.0–28.0 29.0–43.0 ≥44.0 <0.001
γ-GT (IU/L), cutoff in women ≤13.0 14.0–17.0 18.0–25.0 ≥26.0 <0.001
Age (years) at survey, mean (SD) 55.0 (10.8) 55.8(10.5) 56.4(10.3) 56.3(9.9) <0.001
Age ≥60 years, N (%) 522,568 (31.3) 551,870 (34.0) 610,178 (35.9) 559,414 (35.0) <0.001
Follow-up duration (years), mean (SD) 7.7 (1.2) 7.7 (1.2) 7.6 (1.2) 7.6 (1.3) <0.001
Men, N (%) 575,297 (34.5) 675,673 (41.6) 606,913 (35.7) 610,100 (38.1) <0.001
Dementia, N (%) 64,217 (3.9) 64,442 (4.0) 73458 (4.3) 70540 (4.4) <0.001
BMI (kg/m2), mean (SD) 22.9 (2.7) 23.6 (2.8) 24.3 (3.0) 24.9 (3.2) <0.001
Obesity, N (%)* 331,383 (20) 467,720 (29) 647,821 (38) 752,397 (47) <0.001
SBP (mmHg), mean (SD) 121.3 (15.9) 123.6 (15.9) 125.5 (16.1) 127.5 (16.3) <0.001
DBP (mmHg), mean (SD) 75.0 (10.1) 76.6 (10.1) 77.7 (10.2) 79.0 (10.4) <0.001
FPG (mg/dL), mean (SD) 93.6 (18.8) 96.1 (21.8) 98.8 (24.8) 104.1 (30.5) <0.001
Total cholesterol (mg/dL), mean (SD) 188.2 (33.7) 196.0 (35.0) 202.1 (36.9) 206.9 (39.8) <0.001
AST (U/L), median (IQR) 21.8 (21.8–21.8) 23.0 (23.0–23.0) 24.3 (24.3–24.3) 29.3 (29.3–29.3) <0.001
ALT (U/L), median (IQR) 17.1 (17.1–17.1) 19.7 (19.7–19.7) 22.5 (22.5–22.5) 30.7 (30.7–30.7) <0.001
Glycemic status
Normoglycemia, N (%) 1,258,644 (75.5) 1,136,977 (67.0) 1,093,089 (64.2) 883,982 (55.3) <0.001
IFG, N (%) 303,121 (18.2) 347,155 (21.4) 410,325 (24.1) 434,909 (27.2) <0.001
Incident diabetes, N (%) 25,597 (1.5) 35,758 (2.2) 52,362 (3.1) 84,493 (5.3) <0.001
Prevalent diabetes, N (%) 80,609 (4.8) 105,569 (6.5) 146,275 (8.6) 196,406 (12.3) <0.001
Hypertension, N (%) 418,596 (25.1) 512,414 (31.5) 643,843 (37.8) 710,189 (44.4) <0.001
Dyslipidemia, N (%) 199,912 (12.0) 286,018 (17.6) 409,593 (24.1) 498,785 (31.2) <0.001
Myocardial infarction, N (%) 7,896 (0.5) 9,711 (0.6) 11,283 (0.7) 12,338 (0.8) <0.001
Stroke, N (%) 34,742 (2.1) 40,853 (2.5) 49,595 (2.9) 52,954 (3.3) <0.001
Current smoker, N (%) 151,403 (9.1) 192,585 (11.9) 188,063 (11.1) 190,242 (11.9) <0.001
Heavy drinker, N (%) 260,994 (15.7) 298,898 (18.4) 317,239 (18.6) 327,751 (20.5) <0.001
Regular exercise, N (%) 794,907 (47.7) 779,254 (47.9) 785,860 (46.2) 705,416 (44.1) <0.001
Income, lowest quartile, No. (%) 357,888 (21.5) 340,007 (20.9) 360,958 (21.2) 340,367 (21.3) <0.001
Table 2. Sex-specific γ-GT and metabolic parameters. Data for continuous variables were expressed as either 
mean ± standard deviation, or mean (interquartile range) and categorical variables were expressed as number 
(percent). Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
FPG, fasting plasma glucose; γ-GT, gamma-glutamyltransferase; AST, aspartate transaminase; ALT, alanine 
transferase; IFG, impaired fasting glucose. *Obesity was defined as body mass index >25 kg/m2 per Asian-
Pacific definition.
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Interestingly, in our study a strong positive association between serum γ-GT levels and dementia risk was 
observed in the younger age group, particularly in the young male, non-obese group. This is similar to previous 
studies of γ-GT and cardiovascular disease risk18,19. However, the association between γ-GT and dementia is 
independent of cardiovascular disease, as a stronger association was observed in individuals without previous 
myocardial infarction or ischemic stroke. Moreover, considering the smaller effect size of diabetes on EOD than 
LOD17, the degree of impact of γ-GT might be relatively greater on EOD than LOD. γ-GT levels are known to 
reflect vascular and cardiometabolic diseases and γ-GT enzyme activity is independently associated with car-
diovascular disease and cardiovascular-related mortality, in a dose-dependent manner10, suggesting its causal 
relationship to vascular damage. In pooled analysis, higher γ-GT enzyme activity was a surrogate marker for 
diabetes and metabolic syndrome, which contribute to dementia pathogenesis20. Likewise, our study showed a 
relatively prominent impact of γ-GT on VaD compared to AD and a linear association between γ-GT quartiles 
and impaired glucose status. The pathways involved in γ-GT expression and cardiometabolic disease could be 
explained by insulin signaling impairment and insulin resistance21. Furthermore, γ-GT enzyme activity increased 
in all-cause and cancer mortality independently of NAFLD18, suggesting its essential role in human metabo-
lism. γ-GT is primarily involved in extracellular catabolism of glutathione, the major thiol antioxidant that plays 
a protective role against oxidants22. Therefore, an increased serum γ-GT level reflects systemic oxidation and 
reactive oxygen species (ROS). We found more increased and stronger dementia risk according to γ-GT groups 
than NAFLD presence. In addition, one notable finding in our study was the J shape for dementia risk in the dia-
betes group. Individuals with diabetes have fundamentally increased ROS, and more γ-GT might be needed to 
Figure 2. Gamma glutamyltransferase increases the risk of dementia. Risk for (A) overall dementia, (B) early 
onset dementia (age 40–59 years), and (C) late onset dementia (age ≥60 years) according to γ-GT decile. 
Adjusted for age, sex, body mass index, smoking history, alcohol use, regular exercise, hypertension, diabetes, 
dyslipidemia, myocardial infarction, ischemic stroke, and socioeconomic status.
Figure 3. Dementia free survival determination by Kaplan-Meier curve according to γ-GT quartiles. (A) 
Overall dementia, (B) Alzheimier’s disease, and (C) vascular dementa. Lowest γ-GT quartile (black solid), 2nd 
γ-GT quartile (red solid), 3rd γ-GT quartile (green solid), and highest γ-GT quartile (blue solid).
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compensate for this stress. If genetically or environmentally γ-GT concentration is decreased, the role of γ-GT in 
this defense mechanism would be impaired, with greater vulnerability to those conditions.
We acknowledge some limitations in the current study. First, this study was based on a national general health 
care dataset, which did not survey genetic factors such as APOE genotype. Second, we could not determine 
the dietary and lifestyle factors which could affect serum γ-GT concentration. However, we did adjust for alco-
hol consumption, which is a generally well-established γ-GT level determinant. Third, our analyses focused on 
dementia type based on diagnosis code rather than imaging or functional cognitive testing. Despite these limita-
tions, our study has several strengths. First, as a large, population-based study, we achieved statistical reliability 
without selection bias. We were able to categorize into sex-specific γ-GT deciles or quintiles, while previous 
studies on NAFLD or γ-GT were conducted mostly in male subjects. Second, to our knowledge, this is the first 
study to demonstrate individual and combined effects of γ-GT and diabetes on development of dementia in the 
general population. Moreover, our results clearly proved the link between γ-GT concentration and dementia risk, 
particularly EOD.
In conclusion, our data demonstrated that γ-GT is positively associated with future risk of dementia inde-
pendent of diabetes and other metabolic conditions. The combined impact of γ-GT and diabetes increased risk 
for dementia development, implying that γ-GT concentration as well as glycemic status could be a risk factor. 
Understanding the role of γ-GT in the pathogenesis of dementia could enable clinicians to identify individuals 
most at risk, especially for EOD, with implications for prevention and treatment.
Methods
Study population. This longitudinal cohort study utilized data collected from participants in the National 
Health Insurance database maintained by the Korean National Health Insurance Service (NHIS), the single 
insurer in the Korean public health insurance sector that provides national health examinations for all Koreans. 




rate* HR (95% CI)
Overall dementia γ-GT Q1 64,217 12,804,671 5.01 1 (Referent)
γ-GT Q2 64,442 12,457,297 5.17 1.02 (1.01–1.03)
γ-GT Q3 73,458 13,014,700 5.64 1.06 (1.05–1.07)
γ-GT Q4 70,540 12,130,175 5.81 1.16 (1.15–1.17)
NAFLD(−) 215,192 38,529,781 5.59 1 (Referent)
NAFLD(+) 57,465 11,877,062 4.84 1.08 (1.07–1.09)
Early onset dementia γ-GT Q1 4,117 8,999,668 0.46 1 (Referent)
γ-GT Q2 4,385 8,417,327 0.52 1.00 (0.96–1.04)
γ-GT Q3 5,066 8,542,570 0.59 1.01 (0.97–1.06)
γ-GT Q4 6,347 8,086,032 0.78 1.22 (1.17–1.27)
NAFLD(−) 14,402 26,077,278 0.55 1 (Referent)
NAFLD(+) 5,513 7,968,320 0.69 1.02 (0.98–1.06)
Late onset dementia γ-GT Q1 60,100 3,805,003 15.80 1 (Referent)
γ-GT Q2 60,057 4,039,970 14.87 1.01 (1.00–1.02)
γ-GT Q3 68,392 4,472,130 15.29 1.05 (1.03–1.06)
γ-GT Q4 64,193 4,044,142 15.87 1.13 (1.12–1.14)
NAFLD(−) 200,790 12,452,504 16.12 1 (Referent)
NAFLD(+) 51,952 3,908,742 13.29 1.07 (1.05–1.08)
Alzheimer’s disease γ-GT Q1 47,563 12,804,671 3.71 1 (Referent)
γ-GT Q2 47,166 12,457,297 3.79 1.02 (1.00–1.03)
γ-GT Q3 53,476 13,014,700 4.11 1.05 (1.04–1.06)
γ-GT Q4 50,716 12,130,175 4.18 1.14 (1.13–1.16)
NAFLD(−) 157,748 38,529,781 4.09 1 (Referent)
NAFLD(+) 41,173 11,877,062 3.47 1.07 (1.06–1.09)
Vascular dementia γ-GT Q1 7,350 12,804,671 0.57 1 (Referent)
γ-GT Q2 7,665 12,457,297 0.62 1.02 (0.99–1.05)
γ-GT Q3 9,118 13,014,700 0.70 1.10 (1.06–1.13)
γ-GT Q4 9,310 12,130,175 0.77 1.22 (1.18–1.26)
NAFLD(−) 25,548 38,529,781 0.66 1 (Referent)
NAFLD(+) 7,895 11,877,062 0.66 1.11 (1.08–1.15)
Table 3. Cox model for dementia by γ-GT quartiles and NAFLD. Abbreviation: γ-GT, gamma-glutamyl 
transferase; NAFLD, nonalcoholic fatty liver disease; HR, hazard ratio; 95% CI, 95% confidence interval. 
Adjusted for age, sex, body mass index, smoking status, alcohol use, exercise, hypertension, diabetes, 
dyslipidemia, myocardial infarction, stroke, and socioeconomic status. *dementia incidence rate was expressed 
per 1000 person-years.
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national source to study various diseases24. This biannual regular checkup includes anthropometric measure-
ments, blood pressure, social habits, physical activity, and laboratory tests with overnight fasting. All biochem-
ical samples are collected and measured as previously described25. Past medical history, alcohol consumption, 
smoking history, and exercise habits are collected by standardized self-reporting questionnaires. BMI is calcu-
lated as weight(kg)/height(m2) and obesity is defined as BMI ≥ 25 kg/m2, using the Asian-Pacific criteria26. All 
participants provided written informed consent to participate in the original NHIS. The study was approved 
by the institutional review board of the Yonsei University College of Medicine (4–2016–0575). All procedures 
performed in studies involving human participants were in accordance with the ethical standards of the 1964 






rate* HR (95% CI)
Overall dementia Normoglycemia 142,693 33,676,334 4.24 1 (Referent)
IFG 66,988 11,396,989 5.88 1.06 (1.05; 1.07)
Incident diabetes 11,888 1,481,240 8.03 1.20 (1.18;1.22)
Prevalent diabetes 51,088 3,852,280 13.26 1.60 (1.58; 1.62)
Early onset dementia Normoglycemia 12,207 24,168,225 0.51 1 (Referent)
IFG 4,421 7,324,881 0.60 1.04 (1.00; 1.07)
Incident diabetes 680 899,137 0.76 1.21 (1.12; 1.30)
Prevalent diabetes 2,607 1,653,354 1.58 1.73 (1.66; 1.81)
Late onset dementia Normoglycemia 130,486 9,508,109 13.72 1 (Referent)
IFG 62,567 4,072,107 15.36 1.06 (1.05; 1.07)
Incident diabetes 11,208 582,103 19.25 1.22 (1.20; 1.24)
Prevalent diabetes 48,481 2,198,926 22.05 1.55 (1.53; 1.57)
Alzheimer’s disease Normoglycemia 104,884 33,676,334 3.11 1 (Referent)
IFG 49,063 11,396,989 4.30 1.06 (1.05; 1.07)
Incident diabetes 8,603 1,481,240 5.81 1.18 (1.15; 1.20)
Prevalent diabetes 36,371 3,852,280 9.44 1.57 (1.55; 1.59)
Vascular dementia Normoglycemia 17,098 33,676,334 0.51 1 (Referent)
IFG 8,015 11,396,989 0.70 1.06 (1.03; 1.09)
Incident diabetes 1,500 1,481,240 1.01 1.27 (1.21; 1.34)
Prevalent diabetes 6,830 3,852,280 1.77 1.67 (1.62; 1.72)
Table 4. Cox model for dementia by glycemic status. Abbreviation: IFG, impaired fasting glucose; HR, hazard 
ratio; 95% CI, 95% confidence interval. Adjusted for age, sex, body mass index, smoking status, alcohol use, 
exercise, hypertension, diabetes, dyslipidemia, myocardial infarction, stroke, and socioeconomic status. 
*Dementia incidence rate was expressed per 1000 person-years.
Figure 4. Dementia free survival determination by Kaplan-Meier curve according to glycemic status. (A) 
Overall dementia, (B) Alzheimier’s disease, and (C) vascular dementa. Normoglycemia (black solid), impaired 
fasting glucose (red solid), incident diabetes (green solid), and prevalent diabetes (blue solid).
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Definition of dementia and diabetes. To obtain information on incident dementia, we followed a 
cohort of 6,595,271 participants who were ≥40 years and were dementia-free NHIS beneficiaries (Fig. 1). 
Incident dementia was defined as having a diagnostic code of dementia (International Statistical Classification 
of Disease and Related Health Problems, 10th revision, [ICD-10] codes F00, G30, F01, F02, F03, G23.1, G31.0, 
G31.1, G31.82, G31.83, G31.88, and F10.7) with simultaneous prescription of an anti-dementia medication. 
Anti-dementia medications consisted of an acetylcholinesterase inhibitor (rivastigmine, galantamine, or aricept) 
or N-methyl-D-aspartate receptor antagonist (memantine). Patients with dementia were grouped into AD (ICD-
10 codes F00, G30) or VaD (ICD-10 code F01) for subgroup analyses. The date of dementia diagnosis was the 
date when prescription of an anti-dementia medication and a dementia code coincided. The type of dementia was 
defined as the first diagnosis code of dementia. The index period was from January 1, 2007 to December 31, 2008. 











Normoglycemia 1 (referent) 1 (referent) 1 (referent) 1 (referent) 1 (referent)
IFG 1.06 (1.05–1.07) 1.04 (1.01–1.07) 1.06 (1.05–1.07) 1.06 (1.05–1.07) 1.06 (1.03–1.09)
Incident diabetes 1.20 (1.18–1.22) 1.21 (1.12–1.30) 1.22 (1.20–1.24) 1.18 (1.15–1.20) 1.27 (1.21–1.34)
Treatment maintenance 1.59 (1.57–1.60) 1.70 (1.62–1.78) 1.54 (1.52–1.55) 1.56 (1.54–1.58) 1.65 (1.60–1.70)
Treatment failure 1.71 (1.66–1.76) 2.07 (1.83–2.34) 1.68 (1.64–1.73) 1.63 (1.58–1.68) 1.86 (1.73–2.01)
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Table 5. Risk for dementia by diabetes treatment status. Data were expressed as hazard ratio (95% confidence 
interval). Abbreviation: IFG, impaired fasting glucose. Adjusted for age, sex, body mass index, smoking status, 
alcohol use, exercise, hypertension, diabetes, dyslipidemia, myocardial infarction, stroke, and socioeconomic 
status.
Figure 5. Hazard ratios for dementia according to γ-GT quartiles and glycemic status. Risk for (A) overall 
dementia, (B) Alzheimer’s disease, (C) vascular dementia. (A-C: normoglycemic with lowest γ-GT quartile 
as referent), (D) overall dementia, (E) early onset dementia (age 40–59 years), and (F) late onset dementia 
(age ≥60 years) (D-F: lowest γ-GT quartile in each glycemic status as referent). Adjusted for age, sex, body 
mass index, smoking history, alcohol use, regular exercise, hypertension, dyslipidemia, myocardial infarction, 
ischemic stroke, and income.
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dose-response relationship between serum γ-GT and dementia incidence, we categorized sex-specific γ-GT by 
quartile or decile. In addition, we divided by age at the time of study recruitment (40–59, ≥60 years) to designate 
as EOD (40–59 years) and LOD ( ≥ 60 years)27. NAFLD was estimated by a calculating hepatic steatosis index 
(HSI) and defined by HSI ≥ 3628.
A diagnosis of diabetes based on ICD-10 codes included the principal diagnosis and up to four accompany-
ing diagnoses. To investigate the effect of diabetes and γ-GT, we categorized subjects into 4 groups according to 
glycemic status: 1) Prevalent diabetes was defined as at least one service claim with a diagnosis of diabetes, either 
in outpatient or inpatient care and at least one prescription of a hypoglycemic agents during the index period; 2) 
Figure 6. Hazard ratios and 95% confidence intervals for dementia incidence according to γ-GT quartile by 
gender, age, alcohol use, and comorbidities.
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Incident diabetes was defined as individuals without diabetes diagnosis or treatment, but whose fasting glucose 
concentration was ≥126 mg/dL; 3) IFG was defined as fasting glucose concentration ≥100 mg/dL and <126 mg/
dL; and 4) Others were identified as normoglycemia. In addition, we defined subject who had diabetes diagnosis 
code and prescribed medication, but did not maintain (less than 3 years) the prescribed medication as treatment 
failure group whereas maintained the anti-diabetic medication prescription more than 3 years as treatment main-
tenance group.
Hypertension was defined as ICD-10 codes (I10–13, I15) plus treatment with anti-hypertensive agents, or 
systolic or diastolic blood pressure ≥140 mmHg/≥90 mmHg; dyslipidemia was ICD-10 code of E78 plus treat-
ment with lipid-lowering agents or total cholesterol ≥240 mg/dL. A previous medical history of ischemic stroke 
or myocardial infarction was defined as ICD-10 codes of I63-I64 or I21-I22. We identified low social economic 
status as the lowest quartile for income in the study population29. Heavy alcohol consumption was defined as ≥ 
30 g per day, and regular exercise was categorized as ≥3 times per week of moderate to vigorous physical activity.
Statistical analysis. Descriptive characteristics were mainly presented as mean ± standard deviation (SD). 
As AST, ALT, and γ-GT were not normally distributed, those markers were expressed as median with interquar-
tile range (IQR). As a sex difference in γ-GT level has been documented30, we categorized sex-specific cut-off. 
Data were expressed as numbers and as a frequency percentage. The χ2 test was used to determine differences 
in percentages of categorical variables, and the independent Student’s t test evaluated differences between the 
means of two continuous variables. A one-way analysis of variance (ANOVA) was used to compare the baseline 
characteristics of continuous variables by γ-GT categories. Incidence rates were expressed as events per 1,000 
person-years, and were adjusted for age and sex using the direct method. Cox proportional hazards regression 
analysis was used to identify the association between γ-GT level and dementia after adjustment for other risk 
factors. The results were presented as HRs and 95% CI. Subgroup analysis was performed according to covariates 
including sex, age, hypertension, previous cardiovascular disease (ischemic stroke and myocardial infarction) 
history, obesity, and alcohol consumption. Dementia-free survival according to γ-GT categories and glycemic 
status was analyzed using the Kaplan-Meier curve and expressed as adjusted HR and 95% CI. A two-sided P value 
<0.05 was considered statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS 
Institute, Cary, NC).
Ethics approval and consent to participate. All participants provided written informed consent to par-
ticipate in the original NHIS. The study was approved by the institutional review board of the Yonsei University 
College of Medicine (4–2016–0575).
Data availability
This study used the National Health Insurance Service NHIS 2009–2015 data, which were released by the KNHIS. 
Access to NHIS-NSC data are available from the website of NHIS (https:// nhiss.nhis.or.kr) after completing the 
application process and receiving approval (http://nhiss.nhis. or.kr/bd/ab/bdaba021eng.do).
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